TY - JOUR
T1 - Inhibiting Effect of Zinc Oxide Nanoparticles on Advanced Glycation Products and Oxidative Modifications
T2 - a Potential Tool to Counteract Oxidative Stress in Neurodegenerative Diseases
AU - Ashraf, Jalaluddin M.
AU - Ansari, Mohammad Azam
AU - Fatma, Sana
AU - Abdullah, Saleh M.S.
AU - Iqbal, Johar
AU - Madkhali, Aymen
AU - Hamali, Al Hassan
AU - Ahmad, Saheem
AU - Jerah, Ahmed
AU - Echeverria, Valentina
AU - Barreto, George E.
AU - Ashraf, Ghulam Md
N1 - Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Advanced glycation end products (AGEs) are implicated in several central nervous system (CNS) pathologies including Alzheimer and Parkinson’s diseases. In the face-off of AGE menace, we have attempted to investigate the zinc oxide nanoparticle (ZnONP) role in inhibition of AGE formation. Synthesized ZnONPs were used to investigate the inhibitory effects on AGE formation. The inhibitory effects of ZnONPs on AGE formation were determined by biophysical immunological and biochemical techniques. The results showed that ZnONP is a potential anti-glycating agent inhibiting AGE formation as well as protecting the protein structure from change. Therefore, our findings suggest ZnONPs may be used as a therapeutic in resolving the AGE role in CNS-related complications.
AB - Advanced glycation end products (AGEs) are implicated in several central nervous system (CNS) pathologies including Alzheimer and Parkinson’s diseases. In the face-off of AGE menace, we have attempted to investigate the zinc oxide nanoparticle (ZnONP) role in inhibition of AGE formation. Synthesized ZnONPs were used to investigate the inhibitory effects on AGE formation. The inhibitory effects of ZnONPs on AGE formation were determined by biophysical immunological and biochemical techniques. The results showed that ZnONP is a potential anti-glycating agent inhibiting AGE formation as well as protecting the protein structure from change. Therefore, our findings suggest ZnONPs may be used as a therapeutic in resolving the AGE role in CNS-related complications.
KW - Advanced glycation end products
KW - Anti-glycating agent
KW - Nanoparticles
KW - Neurodegenerative diseases
UR - http://www.scopus.com/inward/record.url?scp=85041513029&partnerID=8YFLogxK
U2 - 10.1007/s12035-018-0935-x
DO - 10.1007/s12035-018-0935-x
M3 - Article
C2 - 29423819
AN - SCOPUS:85041513029
SN - 0893-7648
VL - 55
SP - 7438
EP - 7452
JO - Molecular Neurobiology
JF - Molecular Neurobiology
IS - 9
ER -